Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Endeavor Biomedicines, Inc.
Reveal Pharmaceuticals Inc.
Washington University School of Medicine
Stanford University
Columbia University
Mayo Clinic
Virginia Commonwealth University
Hospices Civils de Lyon
Kintara Therapeutics, Inc.
Kintara Therapeutics, Inc.
Oblato, Inc.
Istari Oncology, Inc.
Mayo Clinic
Washington University School of Medicine
Cedars-Sinai Medical Center
The University of Hong Kong
University of Pittsburgh
National Cancer Institute (NCI)
University of Florida
National Cancer Institute (NCI)
University of Sao Paulo
Jonsson Comprehensive Cancer Center
Virginia Commonwealth University
Radiation Therapy Oncology Group
Celgene
Memorial Sloan Kettering Cancer Center
Candel Therapeutics, Inc.
Assistance Publique - Hôpitaux de Paris
Exelixis
Novartis
National Institutes of Health Clinical Center (CC)
Novartis
Duke University
TVAX Biomedical
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Mayo Clinic
Medicenna Therapeutics, Inc.
Eisai Inc.
NYU Langone Health
Northwestern University
Duke University
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Baylor College of Medicine
DNAtrix, Inc.